Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.50) by 20.4 percent. This is a 4.74 percent decrease over losses of $(1.90) per share from the same period last year. The company reported quarterly sales of $364.252 million which beat the analyst consensus estimate of $353.178 million by 3.14 percent. This is a 71.17 percent increase over sales of $212.802 million the same period last year.